The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


The Journal of Immunology, 2007, 178, 7667 -7677
Copyright © 2007 by The American Association of Immunologists, Inc.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Selvaraj, R. K.
Right arrow Articles by Geiger, T. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Selvaraj, R. K.
Right arrow Articles by Geiger, T. L.
Right arrowPubmed/NCBI databases
*Substance via MeSH

A Kinetic and Dynamic Analysis of Foxp3 Induced in T Cells by TGF-beta1

Ramesh K. Selvaraj and Terrence L. Geiger2

Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN 38105

TGF-beta induces Foxp3 expression in stimulated T cells. These Foxp3+ cells (induced regulatory T cells (iTreg)) share functional and therapeutic properties with thymic-derived Foxp3+ regulatory T cells (natural regulatory T cells (nTreg)). We performed a single-cell analysis to better characterize the regulation of Foxp3 in iTreg in vitro and assess their dynamics after transfer in vivo. TGF-beta up-regulated Foxp3 in CD4+Foxp3 T cells only when added within a 2- to 3-day window of CD3/CD28 stimulation. Up to 90% conversion occurred, beginning after 1–2 days of treatment. Foxp3 expression strictly required TCR stimulation but not costimulation and was independent of cell cycling. Removal of TGF-beta led to a loss of Foxp3 expression after an ~4-day lag. Most iTreg transferred into wild-type mice down-regulated Foxp3 within 2 days, and these Foxp3 cells were concentrated in the blood, spleen, lung, and liver. Few of the Foxp3 cells were detected by 28 days after transfer. However, some Foxp3+ cells persisted even to this late time point, and these preferentially localized to the lymph nodes and bone marrow. CXCR4 was preferentially expressed on Foxp3+ iTreg within the bone marrow, and CD62L was preferentially expressed on those in the lymph nodes. Like transferred nTreg and in contrast with revertant Foxp3 cells, Foxp3+ iTreg retained CD25 and glucocorticoid-induced TNFR family-related gene. Thus, Foxp3 expression in naïve-stimulated T cells is transient in vitro, dependent on TGF-beta activity within a highly restricted window after activation and continuous TGF-beta presence. In vivo, a subset of transferred iTreg persist long term, potentially providing a lasting source for regulatory activity after therapeutic administration.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by National Institutes of Health Grant R01 AI056153 (to T.L.G.) and by the American Lebanese Syrian Associated Charities/St. Jude Children’s Research Hospital (to T.L.G. and R.K.S.).

2 Address correspondence and reprint requests to Dr. Terrence L. Geiger, Department of Pathology, St. Jude Children’s Research Hospital, 332 North Lauderdale Street, D-4047, Memphis, TN 38105. E-mail address: terrence.geiger{at}stjude.org

3 Abbreviations used in this paper: Treg, regulatory T cell; GITR, glucocorticoid-induced TNFR family-related gene; iTreg, induced Treg; nTreg, natural Treg; LN, lymph node; rhIL-2, recombinant human IL-2; CD62L, CD62 ligand.




This article has been cited by other articles:


Home page
J. Immunol.Home page
M. Kuczma, I. Pawlikowska, M. Kopij, R. Podolsky, G. A. Rempala, and P. Kraj
TCR Repertoire and Foxp3 Expression Define Functionally Distinct Subsets of CD4+ Regulatory T Cells
J. Immunol., September 1, 2009; 183(5): 3118 - 3129.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Nagata, T. Ise, and I. Pastan
Fc Receptor-Like 3 Protein Expressed on IL-2 Nonresponsive Subset of Human Regulatory T Cells
J. Immunol., June 15, 2009; 182(12): 7518 - 7526.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. R. Kiesel, Z. S. Buchwald, and R. Aurora
Cross-Presentation by Osteoclasts Induces FoxP3 in CD8+ T Cells
J. Immunol., May 1, 2009; 182(9): 5477 - 5487.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. Samanta, B. Li, X. Song, K. Bembas, G. Zhang, M. Katsumata, S. J. Saouaf, Q. Wang, W. W. Hancock, Y. Shen, et al.
TGF-{beta} and IL-6 signals modulate chromatin binding and promoter occupancy by acetylated FOXP3
PNAS, September 16, 2008; 105(37): 14023 - 14027.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
J. Kaplan, L Woodworth, K Smith, J Coco, A Vitsky, and J. McPherson
Therapeutic benefit of treatment with anti-thymocyte globulin and latent TGF-{beta}1 in the MRL/lpr lupus mouse model
Lupus, September 1, 2008; 17(9): 822 - 831.
[Abstract] [PDF]


Home page
J. Immunol.Home page
F. Guo, C. Iclozan, W.-K. Suh, C. Anasetti, and X.-Z. Yu
CD28 Controls Differentiation of Regulatory T Cells from Naive CD4 T Cells
J. Immunol., August 15, 2008; 181(4): 2285 - 2291.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. Godebu, D. Summers-Torres, M. M. Lin, B. J. G. Baaten, and L. M. Bradley
Polyclonal Adaptive Regulatory CD4 Cells That Can Reverse Type I Diabetes Become Oligoclonal Long-Term Protective Memory Cells
J. Immunol., August 1, 2008; 181(3): 1798 - 1805.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. S. Lages, I. Suffia, P. A. Velilla, B. Huang, G. Warshaw, D. A. Hildeman, Y. Belkaid, and C. Chougnet
Functional Regulatory T Cells Accumulate in Aged Hosts and Promote Chronic Infectious Disease Reactivation
J. Immunol., August 1, 2008; 181(3): 1835 - 1848.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
S. Sehrawat, S. Suvas, P. P. Sarangi, A. Suryawanshi, and B. T. Rouse
In Vitro-Generated Antigen-Specific CD4+ CD25+ Foxp3+ Regulatory T Cells Control the Severity of Herpes Simplex Virus-Induced Ocular Immunoinflammatory Lesions
J. Virol., July 15, 2008; 82(14): 6838 - 6851.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Takaki, K. Ichiyama, K. Koga, T. Chinen, G. Takaesu, Y. Sugiyama, S. Kato, A. Yoshimura, and T. Kobayashi
STAT6 Inhibits TGF-{beta}1-mediated Foxp3 Induction through Direct Binding to the Foxp3 Promoter, Which Is Reverted by Retinoic Acid Receptor
J. Biol. Chem., May 30, 2008; 283(22): 14955 - 14962.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
M. J. Richer, N. Straka, D. Fang, I. Shanina, and M. S. Horwitz
Regulatory T-Cells Protect From Type 1 Diabetes After Induction by Coxsackievirus Infection in the Context of Transforming Growth Factor-{beta}
Diabetes, May 1, 2008; 57(5): 1302 - 1311.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Rynda, M. Maddaloni, D. Mierzejewska, J. Ochoa-Reparaz, T. Maslanka, K. Crist, C. Riccardi, B. Barszczewska, K. Fujihashi, J. R. McGhee, et al.
Low-Dose Tolerance Is Mediated by the Microfold Cell Ligand, Reovirus Protein {sigma}1
J. Immunol., April 15, 2008; 180(8): 5187 - 5200.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
S. Haxhinasto, D. Mathis, and C. Benoist
The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells
J. Exp. Med., March 17, 2008; 205(3): 565 - 574.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. K. Selvaraj and T. L. Geiger
Mitigation of Experimental Allergic Encephalomyelitis by TGF-{beta} Induced Foxp3+ Regulatory T Lymphocytes through the Induction of Anergy and Infectious Tolerance
J. Immunol., March 1, 2008; 180(5): 2830 - 2838.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
I. Moisini, P. Nguyen, L. Fugger, and T. L. Geiger
Redirecting Therapeutic T Cells against Myelin-Specific T Lymphocytes Using a Humanized Myelin Basic Protein-HLA-DR2-{zeta} Chimeric Receptor
J. Immunol., March 1, 2008; 180(5): 3601 - 3611.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2007 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2007 by The American Association of Immunologists, Inc. All rights reserved.